MedTrace Logo

Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age "Scoped for Japanese"

NCT01897766 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 482

Last updated 2023-09-25

Study results available
· View outcomes & findings →

Summary

The objective of this surveillance is to collect Safety and Effectiveness information for Long term Use of Somatropin for Patients with a Small for Gestational Age (SGA).

Conditions

  • Small for Gestational Age (SGA)

Interventions

DRUG

Somatropin

0.23 mg to 0.48 mg/kg/week

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
2 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-05
Primary Completion
2017-02-28
Completion
2017-06-07

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01897766 on ClinicalTrials.gov